公司计划通过实施上述项目，进一步提升利用信息系统服务医疗器械流通的精细化、智能化管理能力，进一步加强自身在产业链环的服务属性，促进产品多 元化和上下游一体化发展，为客户提供高品质的服务，增强客户粘性。 招股书显示，建发致新作为全国性的高值医疗器械流通商，主要从事医疗器械直销及分销业务，并为终端医院提供医用耗材集约化运营（SPD）等服务。经 过多年的发展，公司深入研究传统器械流通业务开展过程中的痛点和挖掘产业链上下游各环节的需求，积极探索行业变革方向，积累了丰富的业务运营及服 务经验，在医疗器械流通领域拥有一定市场地位。公司拟通过本次上市募集资金提升信息系统服务医疗器械流通的精细化、智能化管理能力，同时优化自身 财务结构、降低自身经营风险。 据招股书，为巩固企业经营成果，持续加强企业竞争优势，建发致新未来发展规划包括以下几个方面： 第一，在保证公司血管介入类核心产品销售规模增 长的同时，努力扩大在IVD、外科、口腔、眼科等医疗器械产品领域的销售规模，以夯实公司规模化发展的基础； 第二，公司将进一步加强与医疗器械上 游厂商的合作，从渠道准入管理、物流管理、存货管理、信息管理等多维度为上游厂商提供高效、扁平、集约的 ...

Core Viewpoint - The company, Jianfa Zhixin, is officially launching its IPO process on the Shenzhen Stock Exchange's ChiNext board, focusing on the medical device distribution industry and aiming to enhance its digital capabilities and service offerings in the healthcare sector [1][2]. Group 1: Company Overview - Jianfa Zhixin was established in 2010 and primarily engages in direct sales and distribution of medical devices, providing services such as SPD to hospitals [2]. - The company has developed a nationwide distribution network, serving over 3,300 medical institutions across 31 provinces in China, with a focus on high-value interventional products [2]. - Jianfa Zhixin has established long-term partnerships with over 100 well-known domestic and international medical device manufacturers, leveraging its strong channel coverage and professional operations [2]. Group 2: Financial Performance - From 2022 to 2024, Jianfa Zhixin's projected revenue is expected to grow from 11.882 billion yuan to 17.923 billion yuan, reflecting a compound annual growth rate (CAGR) of 22.81% [3]. - The company's main revenue source is its direct sales business, which is projected to increase from 7.797 billion yuan in 2022 to 11.032 billion yuan in 2024 [3]. - The revenue growth is attributed to the rapid increase in authorized brands and product lines, as well as the integrated development of direct and distribution businesses [3]. Group 3: Investment and Technology - Jianfa Zhixin plans to use the funds raised from the IPO to invest in digitalization and centralized management of medical consumables, enhancing its management capabilities [1][5]. - The company has developed various proprietary software systems to improve its information management and operational efficiency, holding 45 software copyrights as of the date of the prospectus [5]. - The planned allocation of raised funds includes 140 million yuan for information system upgrades, 104 million yuan for centralized operation services, and 240 million yuan for working capital [5]. Group 4: Future Outlook - Jianfa Zhixin aims to become a leading medical device distribution service provider in China by enhancing its service attributes and expanding its product diversification and integration along the supply chain [1][3]. - The company is focused on scaling its operations while ensuring compliance and information-driven management in the evolving healthcare landscape [3].

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $139.6 million, a 3% increase year-over-year and a 5% increase sequentially, driven by strong demand in aerospace, defense, industrial markets, and select medical applications [9][10] - Gross margin reached a record 33.2%, up 100 basis points sequentially and 330 basis points year-over-year, attributed to a favorable mix, higher volumes, and improved operating discipline [6][13] - Net income increased to $5.6 million or $0.34 per diluted share, with adjusted net income at $9.5 million or $0.57 per diluted share, up from $0.46 in Q1 and $0.29 in the prior year [14][15] - Operating cash flow was a record $24.5 million, up 76% sequentially and nearly three times the level from the same period last year [17][18] Business Line Data and Key Metrics Changes - Aerospace and defense revenue grew 13%, reflecting strong execution and program timing [10] - Medical revenue increased by 4%, driven by solid demand for surgical instruments [11] - Industrial market revenue rose by 3%, supported by strength in HVAC and data center applications [11] - Vehicle revenue decreased by 7% due to ongoing softness in powersports, although there was sequential improvement [11][12] Market Data and Key Metrics Changes - Sales to U.S. customers accounted for 55% of total revenue, consistent with the previous year [9] - The backlog at the end of the quarter was $236.6 million, slightly down from Q1 and prior year levels, as customers managed through inventory normalization [21] - Demand trends in key sectors like industrial and aerospace and defense remain steady, with signs of recovery in industrial automation [21][23] Company Strategy and Development Direction - The company is focused on sustainable, profitable growth while delivering value to customers, employees, and shareholders [22] - The "Simplify to Accelerate Now" program is central to performance, driving efficiency and responsiveness across global operations [6][23] - The company is proactively managing external risks, including tariffs and supply dynamics related to rare earth materials [23] Management's Comments on Operating Environment and Future Outlook - Management noted that the destocking cycle appears to be largely behind them, with order activity becoming more consistent [21] - There is cautious optimism regarding the recovery in industrial automation and steady momentum in aerospace and defense [23] - The company expects Q3 sales to be sequentially lower due to revenue pulled into Q2, but remains confident in long-term growth prospects [22] Other Important Information - The company reduced debt by $20 million during the quarter, bringing net debt down by $35.8 million year-to-date [19] - Capital expenditures for the first half of the year were $3.2 million, with a revised full-year outlook of $8 million to $10 million [19] Q&A Session Summary Question: Insights on destocking and industrial demand - Management confirmed that destocking appears to be in the rearview mirror, with positive signs in industrial demand [29] Question: Aerospace and defense exposure and demand visibility - Management highlighted strong long-term visibility in aerospace and defense, with ongoing improvements in operating capabilities [30][31] Question: Rare earth magnets risk profile - Management expressed cautious optimism regarding supply chain improvements but acknowledged ongoing risks related to sourcing from China [34][35] Question: Revenue pull forward sources - The majority of revenue pull forward came from medical, high-end industrial, and defense segments [46][48] Question: Capacity for data center demand - Management confirmed that they are increasing capacity to meet growing demand in the data center market [82] Question: Automation market recovery - Management noted signs of normalization in the automation market, expecting positive impacts moving forward [85][86] Question: Munitions business capacity constraints - Management stated that they are not capacity constrained in the munitions business and have seen increased orders [90][91]

Core Viewpoint - The pharmaceutical industry in China is facing significant challenges in IPOs, with only five new drug companies expected to list in 2024, a sharp decline compared to previous years. The only remaining candidate on the ChiNext board is Jianfa Zhixin Medical Technology Group Co., Ltd., which has faced delays in its registration process with the CSRC for nearly 1.5 years [2][3]. Company Overview - Jianfa Zhixin primarily engages in the wholesale of medical devices, boasting substantial revenue of over 10 billion yuan. However, its profitability is concerning, with a gross margin consistently below 10% and a net profit margin nearing 1% [2][4]. - The company has not progressed to the registration stage with the CSRC, likely due to its lack of innovation and issues such as absence of patents and abnormal increases in R&D expenses [2][4]. Financial Performance - Jianfa Zhixin's revenue for the years 2020 to 2023 (first half) was 8.542 billion yuan, 10.024 billion yuan, 11.882 billion yuan, and 7.499 billion yuan, respectively, with net profits of 168 million yuan, 176 million yuan, 189 million yuan, and 103 million yuan [4][11]. - The company's gross margins for the same periods were 6.12%, 7.02%, 7.71%, and 7.72%, indicating a persistent struggle to meet the entrepreneurial board's standards [4][5]. Market Position and Competition - Jianfa Zhixin operates in a low-margin, low-value-added segment of the medical device distribution industry, which contradicts the ChiNext's focus on growth-oriented innovative enterprises [3][9]. - Compared to its peers, Jianfa Zhixin's gross margin is significantly lower, with competitors like Guoyao Holdings and Jiuzhoutong averaging gross margins above 8% [5][6]. R&D and Innovation Concerns - The company has faced scrutiny regarding its R&D expenditures, which have surged from 2.7035 million yuan in 2020 to 16.0078 million yuan in the first half of 2023, raising questions about the authenticity of these expenses [12][13]. - Jianfa Zhixin lacks patents and has only a few software copyrights, leading to doubts about its innovation capabilities. The majority of its R&D spending appears to be on outsourced projects rather than internal development [12][15]. Regulatory Challenges - The company has been questioned by regulators about its compliance with the ChiNext's innovation requirements, particularly regarding its R&D spending and the nature of its business model, which does not involve direct product development [12][16]. - Jianfa Zhixin's significant increase in R&D personnel and expenditures has raised suspicions of "last-minute" efforts to meet regulatory standards, especially given its lack of tangible innovation outputs [15][17].